Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Maybe back to 50 cents

<< Previous

Bullboard Posts

Next >>

Comment by SuperSlugon Aug 04, 2023 8:55am

141 Views

Post# 35572890

RE:Maybe back to 50 cents

So is this just random market noise or is something up? Been bag holding this dawg for years now and would like nothng more than to unload it. The BID is at 64/$.52 premarket with very little on the ASK

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?